These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 9376587)

  • 1. An in vitro analysis of the combination of hemophilia A and factor V(LEIDEN).
    van 't Veer C; Golden NJ; Kalafatis M; Simioni P; Bertina RM; Mann KG
    Blood; 1997 Oct; 90(8):3067-72. PubMed ID: 9376587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation. Synergistic effect in combination with tissue factor pathway inhibitor.
    van 't Veer C; Golden NJ; Kalafatis M; Mann KG
    J Biol Chem; 1997 Mar; 272(12):7983-94. PubMed ID: 9065469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II.
    van 't Veer C; Mann KG
    J Biol Chem; 1997 Feb; 272(7):4367-77. PubMed ID: 9020158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa.
    van 't Veer C; Golden NJ; Mann KG
    Blood; 2000 Feb; 95(4):1330-5. PubMed ID: 10666207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Normal" thrombin generation.
    Butenas S; van't Veer C; Mann KG
    Blood; 1999 Oct; 94(7):2169-78. PubMed ID: 10498586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased tissue factor-initiated prothrombin activation as a result of the Arg506 --> Gln mutation in factor VLEIDEN.
    van 't Veer C; Kalafatis M; Bertina RM; Simioni P; Mann KG
    J Biol Chem; 1997 Aug; 272(33):20721-9. PubMed ID: 9252393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood coagulation in hemophilia A and hemophilia C.
    Cawthern KM; van 't Veer C; Lock JB; DiLorenzo ME; Branda RF; Mann KG
    Blood; 1998 Jun; 91(12):4581-92. PubMed ID: 9616154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low prevalence of the factor V Leiden mutation among "severe" hemophiliacs with a "milder" bleeding diathesis.
    Arbini AA; Mannucci PM; Bauer KA
    Thromb Haemost; 1995 Nov; 74(5):1255-8. PubMed ID: 8607105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The functional defect of factor VIII Leiden, a genetic variant of coagulation factor VIII.
    Mertens K; van Wijngaarden A; Bertina RM; Veltkamp JJ
    Thromb Haemost; 1985 Oct; 54(3):650-3. PubMed ID: 3937262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A.
    Lee DH; Walker IR; Teitel J; Poon MC; Ritchie B; Akabutu J; Sinclair GD; Pai M; Wu JW; Reddy S; Carter C; Growe G; Lillicrap D; Lam M; Blajchman MA
    Thromb Haemost; 2000 Mar; 83(3):387-91. PubMed ID: 10744141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor V Leiden and hemophilia.
    Franchini M; Lippi G
    Thromb Res; 2010 Feb; 125(2):119-23. PubMed ID: 19932655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.
    Baumgartner CK; Mattson JG; Weiler H; Shi Q; Montgomery RR
    J Thromb Haemost; 2017 Jan; 15(1):98-109. PubMed ID: 27496751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does activated protein C-resistant factor V contribute to thrombin generation in hemophilic plasma?
    Bos MH; Meijerman DW; van der Zwaan C; Mertens K
    J Thromb Haemost; 2005 Mar; 3(3):522-30. PubMed ID: 15748243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemophilia as a defect of the tissue factor pathway of blood coagulation: effect of factors VIII and IX on factor X activation in a continuous-flow reactor.
    Repke D; Gemmell CH; Guha A; Turitto VT; Broze GJ; Nemerson Y
    Proc Natl Acad Sci U S A; 1990 Oct; 87(19):7623-7. PubMed ID: 2120704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders.
    van't Veer C; Mann KG
    Semin Thromb Hemost; 2000; 26(4):367-72. PubMed ID: 11092210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A model for the tissue factor pathway to thrombin. I. An empirical study.
    Lawson JH; Kalafatis M; Stram S; Mann KG
    J Biol Chem; 1994 Sep; 269(37):23357-66. PubMed ID: 8083241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential role of recombinant factor VIIa as a hemostatic agent.
    Hedner U; Erhardtsen E
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated factor VIII enhances thrombin generation in the presence of factor VIII-deficiency, factor XI-deficiency or fondaparinux.
    Szlam F; Sreeram G; Solomon C; Levy JH; Molinaro RJ; Tanaka KA
    Thromb Res; 2011 Feb; 127(2):135-40. PubMed ID: 21144556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteolytic events that regulate factor V activity in whole plasma from normal and activated protein C (APC)-resistant individuals during clotting: an insight into the APC-resistance assay.
    Kalafatis M; Haley PE; Lu D; Bertina RM; Long GL; Mann KG
    Blood; 1996 Jun; 87(11):4695-707. PubMed ID: 8639839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Milder clinical presentation of haemophilia A with severe deficiency of factor VIII as measured by one-stage assay.
    Ghosh K; Shetty S; Mohanty D
    Haemophilia; 2001 Jan; 7(1):9-12. PubMed ID: 11136374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.